Allergan completes $2.9bn acquisition of LifeCell

Allergan has completed its acquisition of LifeCell, a Canada-based regenerative medicine company, for $2.9 billion.

The completion, announced on Wednesday, February 1, means LifeCell’s regenerative medicines business will be added to Allergan’s portfolio of medical aesthetic products, such as breast implants and tissue expanders.

Brent Saunders, chairman and CEO of Allergan, said: “The completion of the LifeCell acquisition is an important milestone for Allergan, serving as our entry point into regenerative medicine as we continue to add to our world-class aesthetic and plastic surgery business.”

Saunders added: “The combination of LifeCell's novel regenerative medicine products coupled with Allergan's innovative medical aesthetics and plastic surgery portfolio creates a more complete product offering for plastic surgeons globally.”

LifeCell’s portfolio includes Acellular Dermal Matrices and Allodem, often used in breast reconstruction procedures, and Revolved, which is used in plastic and reconstructive procedures.

Allergan has also acquired LifeCell’s research and development operations, based in New Jersey.

The acquisition was announced in December last year.